skip to content
Primary navigation

Pradaxa

Drug - Pradaxa  (dabigatran etexilate mesylate) [Boehringer Ingelheim]

August 2014

Therapeutic area - Anticoagulants

Approval criteria

  • Treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days OR
  • Patient has been diagnosed with non-valvular atrial fibrillation, deep vein thrombosis or pulmonary embolism AND
  • Patient has a history of using warfarin and has not been adequately controlled on warfarin therapy as evidenced by INR or bleeds

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top